Aaron Goodman: Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy

Aaron Goodman shared a post on X/Twitter:

“Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy | NEJM
In relapsed/refractory aggressive lymphomas,leukemias CART has a place.
However, we should pause and figure this out before we give CART first line myeloma and smoldering.”

Read further.

Source: Aaron Goodman/X

Aaron Goodman is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.